JP7343483B2 - Ｐｏｌｏ様キナーゼ４の阻害のための併用療法 - Google Patents

Ｐｏｌｏ様キナーゼ４の阻害のための併用療法 Download PDF

Info

Publication number
JP7343483B2
JP7343483B2 JP2020513562A JP2020513562A JP7343483B2 JP 7343483 B2 JP7343483 B2 JP 7343483B2 JP 2020513562 A JP2020513562 A JP 2020513562A JP 2020513562 A JP2020513562 A JP 2020513562A JP 7343483 B2 JP7343483 B2 JP 7343483B2
Authority
JP
Japan
Prior art keywords
inhibitor
cancer
antibody
cfi
immune checkpoint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020513562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533293A (ja
JP2020533293A5 (https=
Inventor
エム． メーソン，ジャクリーン
アール． ブレイ，マーク
ワー マック，タック
フレッチャー，グラハム
Original Assignee
ユニバーシティー ヘルス ネットワーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー ヘルス ネットワーク filed Critical ユニバーシティー ヘルス ネットワーク
Publication of JP2020533293A publication Critical patent/JP2020533293A/ja
Publication of JP2020533293A5 publication Critical patent/JP2020533293A5/ja
Priority to JP2023141415A priority Critical patent/JP2023155459A/ja
Application granted granted Critical
Publication of JP7343483B2 publication Critical patent/JP7343483B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020513562A 2017-09-08 2018-09-07 Ｐｏｌｏ様キナーゼ４の阻害のための併用療法 Active JP7343483B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023141415A JP2023155459A (ja) 2017-09-08 2023-08-31 Ｐｏｌｏ様キナーゼ４の阻害のための併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555718P 2017-09-08 2017-09-08
US62/555,718 2017-09-08
PCT/CA2018/051086 WO2019046949A1 (en) 2017-09-08 2018-09-07 POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023141415A Division JP2023155459A (ja) 2017-09-08 2023-08-31 Ｐｏｌｏ様キナーゼ４の阻害のための併用療法

Publications (3)

Publication Number Publication Date
JP2020533293A JP2020533293A (ja) 2020-11-19
JP2020533293A5 JP2020533293A5 (https=) 2021-09-24
JP7343483B2 true JP7343483B2 (ja) 2023-09-12

Family

ID=65633360

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020513562A Active JP7343483B2 (ja) 2017-09-08 2018-09-07 Ｐｏｌｏ様キナーゼ４の阻害のための併用療法
JP2023141415A Pending JP2023155459A (ja) 2017-09-08 2023-08-31 Ｐｏｌｏ様キナーゼ４の阻害のための併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023141415A Pending JP2023155459A (ja) 2017-09-08 2023-08-31 Ｐｏｌｏ様キナーゼ４の阻害のための併用療法

Country Status (8)

Country Link
US (1) US12109215B2 (https=)
EP (1) EP3678669A4 (https=)
JP (2) JP7343483B2 (https=)
CN (1) CN111225670A (https=)
AU (2) AU2018328773B2 (https=)
CA (1) CA3074876A1 (https=)
TW (1) TWI845482B (https=)
WO (1) WO2019046949A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
JP2023505301A (ja) * 2019-12-06 2023-02-08 ユニバーシティー ヘルス ネットワーク 急性骨髄性白血病または骨髄異形成症候群に対する治療
US20230165871A1 (en) * 2020-04-06 2023-06-01 University Health Network Combination therapies for inhibition of polo-like kinase 4
MX2023013225A (es) 2021-05-11 2024-01-15 Oric Pharmaceuticals Inc Inhibidores de la cinasa 4 similar a polo.
WO2022266240A1 (en) * 2021-06-16 2022-12-22 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5442906B2 (ja) * 2010-04-06 2014-03-19 ユニバーシティ・ヘルス・ネットワーク キナーゼインヒビターおよびこれを用いた癌の治療方法
US8933070B2 (en) * 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
RS58413B1 (sr) * 2013-10-18 2019-04-30 Univ Health Network So i kristalni oblici inhibitora plk-4
SG11201602882VA (en) * 2013-10-18 2016-05-30 Univ Health Network Treatment for pancreatic cancer
ES2686549T3 (es) * 2014-06-16 2018-10-18 Worldwide Innovative Network Método para seleccionar una triterapia personalizada para el tratamiento del cáncer
AU2015327868A1 (en) * 2014-10-03 2017-04-20 Novartis Ag Combination therapies
EP3981430A1 (en) * 2015-01-21 2022-04-13 Memorial Sloan Kettering Cancer Center Methods and compositions for increasing susceptibility to radiation treatment by inhibiting suppression of numerical chromosomal instability of cancer cells
AU2016219204B2 (en) * 2015-02-12 2021-01-21 Beyondspring Pharmaceuticals, Inc. Use of Plinabulin in combination with immune checkpoint inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MASON, J.M., et al.，Cancer Cell，2014年，Vol.26, No.2，pp.163-176.
MASON, J.M., et al.，Proceedings of the National Academy of Sciences，2017年03月21日，Vol.114, No.12，pp.3127-3132.
WOUTERS, M.C.A., et al.，Cancer Immunology, Immunotherapy，2017年04月13日，Vol.66, No.6，pp.811-818.

Also Published As

Publication number Publication date
WO2019046949A1 (en) 2019-03-14
AU2018328773B2 (en) 2023-11-16
JP2020533293A (ja) 2020-11-19
US20210060026A1 (en) 2021-03-04
US12109215B2 (en) 2024-10-08
EP3678669A4 (en) 2021-06-09
TW201919637A (zh) 2019-06-01
EP3678669A1 (en) 2020-07-15
CN111225670A (zh) 2020-06-02
TWI845482B (zh) 2024-06-21
AU2018328773A1 (en) 2020-03-26
AU2024200937A1 (en) 2024-02-29
CA3074876A1 (en) 2019-03-14
JP2023155459A (ja) 2023-10-20

Similar Documents

Publication Publication Date Title
AU2022200196B2 (en) Methods, compositions, and kits for treatment of cancer
JP2023155459A (ja) Ｐｏｌｏ様キナーゼ４の阻害のための併用療法
CN107743401B (zh) 包含抗pd-1抗体和另外的抗体的组合的组合物
US20160031990A1 (en) Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
CN114080228A (zh) Sting激动剂和检查点抑制剂的施用
CN112384219A (zh) Sumo-激活酶抑制剂和抗cd20抗体的施用
CN111973739B (zh) 抗pd-l1单克隆抗体治疗癌症的用途
US20230390294A1 (en) Combination therapies for inhibition of ttk protein kinase
CN113473989B (zh) Sumo活化酶抑制剂和检查点抑制剂的施用
CN113164599B (zh) 抗pd-l1单克隆抗体治疗癌症的用途
CN118829446A (zh) 使用ctla-4和pd-1双特异性抗体的治疗方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210816

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230807

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230831

R150 Certificate of patent or registration of utility model

Ref document number: 7343483

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150